Cwm LLC Grows Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Cwm LLC increased its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 136.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 60,504 shares of the company’s stock after buying an additional 34,887 shares during the period. Cwm LLC’s holdings in Organogenesis were worth $173,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. increased its holdings in shares of Organogenesis by 309.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after acquiring an additional 3,005,450 shares during the last quarter. AQR Capital Management LLC increased its stake in Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Organogenesis during the first quarter worth $1,846,000. Acadian Asset Management LLC lifted its position in shares of Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock worth $8,521,000 after buying an additional 471,741 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after buying an additional 333,123 shares during the period. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Stock Performance

ORGO opened at $2.89 on Thursday. Organogenesis Holdings Inc. has a 1-year low of $1.96 and a 1-year high of $4.70. The company has a market capitalization of $383.13 million, a price-to-earnings ratio of -22.23 and a beta of 1.60. The business has a 50 day moving average price of $2.86 and a two-hundred day moving average price of $2.78. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The business had revenue of $130.23 million for the quarter, compared to analyst estimates of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. Research analysts predict that Organogenesis Holdings Inc. will post -0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Lake Street Capital began coverage on Organogenesis in a research report on Friday, June 28th. They set a “buy” rating and a $5.00 price target on the stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.